JCT  Vol.5 No.8 , July 2014
Bladder-Sparing Approach with Radiotherapy in Patients with Small Cell Carcinoma of the Bladder
ABSTRACT

Small cell carcinoma (SCCB) of the bladder is rare and has a poor prognosis. Because of its rarity, gold standard care has not been established. The purpose of this study was to analyze the feasibility of a bladder-sparing approach. Data for treatments and outcomes in patients with a diagnosis of SCCB who received bladder-sparing treatment in our facility in the period from February 2007 to August 2012 were retrospectively analyzed. Six eligible patients received definitive radiotherapy in the cancer network of Tohoku region. Mean age of the patients was 69.5 years (range: 44 - 83 years), and median follow-up period was 29.2 months (range: 4.1 - 54.5 months). The mean dose was 60 Gy (range: 60 to 63 Gy), and 1.2 - 2.0 Gy was given per fraction. The initial CTV was the whole pelvis or the small pelvis, and it was shrunk to the bladder or tumor as a boost. The 1-year and 3-year overall survival rates were 83.3% and 55.6%, respectively. The 1-year and 3-year local control rates were both 80.0%. Only one patient had local failure. Recurrence or metastasis in sites other than the brain occurred in three (50%) of the patients after primary treatment. Two of those patients did not receive any chemotherapy. None of the patients had serious toxicities, and the bladder could be preserved in all patients. In this study, radiotherapy was effective for patients with SCCB. There was no recurrence in the bladder, and it was possible to preserve the bladder in all patients. Distant metastases were observed frequently, and chemotherapy was considered to be essential. Local treatment with radiotherapy has an important role from the point of view of the patient’s QOL.


Cite this paper
Akamatsu, H. , Nomiya, T. , Harada, M. , Oota, I. , Ichikawa, M. , Miwa, M. , Kuroda, Y. , Takai, K. , Anbai, A. , Kawaguchi, H. , Takai, Y. and Nemoto, K. (2014) Bladder-Sparing Approach with Radiotherapy in Patients with Small Cell Carcinoma of the Bladder. Journal of Cancer Therapy, 5, 797-805. doi: 10.4236/jct.2014.58087.
References
[1]   Cramer, S.F., Aikawa, M., Cebelin, M. and Cebelin, M. (1981) Neurosecretory Granules in Small Cell Invasive Carcinoma of the Urinary Bladder. Cancer, 47, 724-730. http://dx.doi.org/10.1002/1097-0142(19810215)47:4<724::AID-CNCR2820470417>3.0.CO;2-2

[2]   Koay, E.J., Teh, B.S., Paulino, A.C. and Butler, E.B. (2011) A Surveillance, Epidemiology, and End Results Analysis of Small Cell Carcinoma of the Bladder: Epidemiology, Prognostic Variables, and Treatment Trends. Cancer, 117, 5325-5333. http://dx.doi.org/10.1002/cncr.26197

[3]   Koay, E.J., Teh, B.S., Paulino, A.C. and Butler, E.B. (2012) Treatment Trends and Outcomes of Small-Cell Carcinoma of the Bladder. International Journal of Radiation Oncology * Biology * Physics, 83, 64-70. http://dx.doi.org/10.1016/j.ijrobp.2011.05.039

[4]   Walenkamp, A.M., Sonke, G.S. and Sleijfer, D.T. (2009) Clinical and Therapeutic Aspects of Extrapulmonary Small Cell Carcinoma. Cancer Treatment Reviews, 35, 228-236.
http://dx.doi.org/10.1016/j.ctrv.2008.10.007

[5]   van Meerbeeck, J.P., Fennell, D.A. and De Ruysscher, D.K. (2011) Small-Cell Lung Cancer. Lancet, 378, 1741-1755. http://dx.doi.org/10.1016/S0140-6736(11)60165-7

[6]   Schreiber, D., Rineer, J., Weiss, J., Leaf, A., Karanikolas, N., Rotman, M. and Schwartz, D. (2013) Characterization and Outcomes of Small Cell Carcinoma of the Bladder Using the Surveillance, Epidemiology, and End Results Database. American Journal of Clinical Oncology, 36, 126-131.
http://dx.doi.org/10.1097/COC.0b013e3182438c71

[7]   Macedo, L.T., Ribeiro, J., Curigliano, G., Fumagalli, L., Locatelli, M., Carvalheira, J.B., Quintela, A., Bertelli, S. and De Cobelli, O. (2011) Multidisciplinary Approach in the Treatment of Patients with Small Cell Bladder Carcinoma. European Journal of Surgical Oncology, 37, 558-562.
http://dx.doi.org/10.1016/j.ejso.2011.04.005

[8]   Cheng, L., Pan, C.X., Yang, X.J., Lopez-Beltran, A., MacLennan, G.T., Lin, H., Kuzel, T.M., Papavero, V., Tretiakova, M., Nigro, K., et al. (2004) Small Cell Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of 64 Patients. Cancer, 101, 957-962. http://dx.doi.org/10.1002/cncr.20456

[9]   Karpman, E., Goldberg, Z., Saffarian, A., Gandour-Edwards, R., Ellison, L.M. and de Vere White, R.W. (2004) Analysis of Treatment for Small Cell Cancer of the Bladder and Report of Three Cases. Urology, 64, 494-498. http://dx.doi.org/10.1016/j.urology.2004.04.038

[10]   Mukesh, M., Cook, N., Hollingdale, A.E., Ainsworth, N.L. and Russell, S.G. (2009) Small Cell Carcinoma of the Urinary Bladder: A 15-Year Retrospective Review of Treatment and Survival in the Anglian Cancer Network. BJU International, 103, 747-752.
http://dx.doi.org/10.1111/j.1464-410X.2008.08241.x

[11]   Bex, A., Nieuwenhuijzen, J.A., Kerst, M., Pos, F., van Boven, H., Meinhardt, W. and Horenblas, S. (2005) Small Cell Carcinoma of Bladder: A Single-Center Prospective Study of 25 Cases Treated in Analogy to Small Cell Lung Cancer. Urology, 65, 295-299.
http://dx.doi.org/10.1016/j.urology.2004.09.049

[12]   Brenner, B., Tang, L.H., Shia, J., Klimstra, D.S. and Kelsen, D.P. (2007) Small Cell Carcinomas of the Gastrointestinal Tract: Clinicopathological Features and Treatment Approach. Seminars in Oncology, 34, 43-50. http://dx.doi.org/10.1053/j.seminoncol.2006.10.022

[13]   Meng, M.B., Zaorsky, N.G., Jiang, C., Tian, L.J., Wang, H.H., Liu, C.L., Wang, J., Tao, Z., Sun, Y., Pang, Q.S., et al. (2013) Radiotherapy and Chemotherapy Are Associated with Improved Outcomes over Surgery and Chemotherapy in the Management of Limited-Stage Small Cell Esophageal Carcinoma. Radiotherapy & Oncology, 106, 317-322. http://dx.doi.org/10.1016/j.radonc.2013.01.008

[14]   Renner, G. (2007) Small Cell Carcinoma of the Head and Neck: A Review. Seminars in Oncology, 34, 3-14. http://dx.doi.org/10.1053/j.seminoncol.2006.10.024

[15]   Hatoum, G.F., Patton, B., Takita, C., Abdel-Wahab, M., La Fave, K., Weed, D. and Reis, I.M. (2009) Small Cell Carcinoma of the Head and Neck: The University of Miami Experience. International Journal of Radiation Oncology * Biology * Physics, 74, 477-481.
http://dx.doi.org/10.1016/j.ijrobp.2008.08.014

[16]   Auperin, A., Arriagada, R., Pignon, J.P., Le Pechoux, C., Gregor, A., Stephens, R.J., Kristjansen, P.E., Johnson, B.E., Ueoka, H., Wagner, H. and Aisner, J. (1999) Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission. Prophylactic Cranial Irradiation Overview Collaborative Group. New England Journal of Medicine, 341, 476-484.
http://dx.doi.org/10.1056/NEJM199908123410703

[17]   Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., Postmus, P., Collette, L., Musat, E. and Senan, S. (2007) Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. New England Journal of Medicine, 357, 664-672. http://dx.doi.org/10.1056/NEJMoa071780

[18]   Bex, A., Sonke, G.S., Pos, F.J., Brandsma, D., Kerst, J.M. and Horenblas, S. (2010) Symptomatic Brain Metastases from Small-Cell Carcinoma of the Urinary Bladder: The Netherlands Cancer Institute Experience and Literature Review. Annals of Oncology, 21, 2240-2245.
http://dx.doi.org/10.1093/annonc/mdq225

[19]   Siefker-Radtke, A.O., Kamat, A.M., Grossman, H.B., Williams, D.L., Qiao, W., Thall, P.F., Dinney, C.P. and Millikan, R.E. (2009) Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy with Ifosfamide/Doxorubicin and Etoposide. Journal of Clinical Oncology, 27, 2592-2597.

 
 
Top